La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Stryker Gestione

Gestione criteri di controllo 3/4

Stryker's Il CEO è Kevin Lobo, nominato in Oct2012, e ha un mandato di 11.83 anni. la retribuzione annua totale è $ 20.77M, composta da 6.7% di stipendio e 93.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.026% delle azioni della società, per un valore di $ 34.31M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6 anni e 6.3 anni.

Informazioni chiave

Kevin Lobo

Amministratore delegato

US$20.8m

Compenso totale

Percentuale dello stipendio del CEO	6.7%
Mandato del CEO	11.9yrs
Proprietà del CEO	0.03%
Durata media del management	6yrs
Durata media del Consiglio di amministrazione	6.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Kevin Lobo rispetto agli utili di Stryker?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$3b
Mar 31 2024	n/a	n/a	US$3b
Dec 31 2023	US$21m	US$1m	US$3b
Sep 30 2023	n/a	n/a	US$3b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$19m	US$1m	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$16m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	US$13m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$15m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$4b
Dec 31 2018	US$14m	US$1m	US$4b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$14m	US$1m	US$1b

Compensazione vs Mercato: La retribuzione totale di Kevin ($USD 20.77M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 5.83M ).

Compensazione vs guadagni: La retribuzione di Kevin è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Kevin Lobo (59 yo)

11.9yrs

Mandato

US$20,767,847

Compensazione

Mr. Kevin A. Lobo has been the Chief Executive Officer of Stryker Corporation since October 1, 2012 and serves as its President since October 01, 2021. He serves as Chairman of the Board at The Advanced Me...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Kevin Lobo	Chairman	11.9yrs	US$20.77m	0.026% $ 36.2m
Glenn Boehnlein	VP & CFO	8.4yrs	US$6.84m	0.0012% $ 1.6m
Viju Menon	Group President of Global Quality & Operations	6.4yrs	US$4.47m	0.0024% $ 3.3m
J. Pierce	Group President of MedSurg & Neurotechnology	6.1yrs	US$6.49m	0.015% $ 20.7m
Spencer Stiles	Group President of Orthopaedics & Spine	6.1yrs	US$6.49m	0.014% $ 18.7m
William Berry	VP & Chief Accounting Officer	3.1yrs	Nessun dato	0.00078% $ 1.1m
Robert Cohen	CTO and VP of Global R&D - Joint Replacement	no data	Nessun dato	Nessun dato
Alan Douville	VP, Chief Information Officer & Chief Information Security Officer	6yrs	Nessun dato	Nessun dato
Jason Beach	Vice President of Finance & Investor Relations	2.2yrs	Nessun dato	Nessun dato
Robert Fletcher	VP & Chief Legal Officer	5.4yrs	US$2.24m	0.0024% $ 3.4m
Dana McMahon	VP & Chief Compliance Officer	no data	Nessun dato	Nessun dato
Yin Becker	VP of Communications	5.8yrs	Nessun dato	0.0082% $ 11.3m

6.0yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di 0R2S è esperto e expertise (durata media dell'incarico 6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Kevin Lobo	Chairman	11.9yrs	US$20.77m	0.026% $ 36.2m
Lisa Skeete Tatum	Independent Director	4.3yrs	US$319.25k	0.00085% $ 1.2m
Howard Cox	Director Emeritus	6.3yrs	US$38.86k	Nessun dato
John Brown	Chairman Emeritus	no data	US$286.99k	5.26% $ 7.2b
Ronda Stryker	Independent Director	40.7yrs	US$319.25k	4.83% $ 6.6b
Mary Brainerd	Independent Director	7.1yrs	US$334.25k	0.0015% $ 2.1m
Allan Golston	Independent Director	13.7yrs	US$334.25k	0.0039% $ 5.4m
Sherilyn S. McCoy	Lead Independent Director	6.3yrs	US$359.25k	0.00022% $ 301.4k
Rajeev Suri	Independent Director	6.3yrs	US$319.25k	0.0014% $ 1.9m
Giovanni Caforio	Independent Director	3.8yrs	US$319.25k	0.00067% $ 917.9k
Andrew Silvernail	Independent Director	10.8yrs	US$339.25k	0.0015% $ 2.0m
Rachel Ruggeri	Independent Director	less than a year	Nessun dato	0.000010% $ 13.7k

6.3yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0R2S sono considerati esperti (durata media dell'incarico 6.3 anni).

Stryker Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

VP & CFO recently sold US$6.7m worth of stock

VP & CFO recently sold US$3.3m worth of stock

Independent Director recently sold US$100m worth of stock

Insufficient new directors

Stryker Corporation, Annual General Meeting, May 09, 2024

Stryker Corporation Announces Dr. Srikant Datar Will Retire from Board of Directors

Recent updates

Upcoming dividend of US$0.80 per share

Stryker Corporation (NYSE:SYK) acquired NICO Corporation.

Stryker Corporation (NYSE:SYK) completed the acquisition of Care.ai inc.

Stryker Corporation (NYSE:SYK) acquired The Osteotomy Truss System (OTS) and Ankle Truss System of 4WEB Inc.

Stryker Corporation (NYSE:SYK) entered into a definitive agreement to acquire Vertos Medical Inc.

Stryker Corporation (NYSE:SYK) agreed to acquire Care.ai inc.

Second quarter dividend of US$0.80 announced

Stryker Announces Launch of Pangea Plating System

VP & CFO recently sold US$6.7m worth of stock

Stryker's Spine Guidance 5 Software Featuring Copilot Receives 510(K) Clearance from FDA

Second quarter 2024 earnings released: EPS: US$2.17 (vs US$1.94 in 2Q 2023)

Stryker Corporation (NYSE:SYK) completed the acquisition of Artelon, Inc.

Stryker Corporation to Report Q2, 2024 Results on Jul 30, 2024

Stryker Releases Lifepak 35 Monitor/Defibrillator

Stryker Corporation (NYSE:SYK) agreed to acquire Artelon, Inc.

First European Announces That Surgeries Completed Using Stryker’s Gamma4 Hip Fracture Nailing System

VP & CFO recently sold US$3.3m worth of stock

First quarter dividend of US$0.80 announced

Stryker Corporation Provides Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$2.07 (vs US$1.56 in 1Q 2023)

Stryker Corporation to Report Q1, 2024 Results on Apr 30, 2024

Stryker Launches Gamma4 Hip Fracture Nailing System in Europe

Upcoming dividend of US$0.80 per share

Fourth quarter dividend of US$0.80 announced

New minor risk - Insider selling

Independent Director recently sold US$100m worth of stock

Stryker Announces the Launch of Prophecy Footprint, an Expansion of the Prophecy Surgical Planning System, Offering Comprehensive Surgical Planning Across the Entire Foot

Full year 2023 earnings released: EPS: US$8.34 (vs US$6.24 in FY 2022)

Stryker Corporation Provides Earnings Guidance for the Year 2024

Insufficient new directors

Upcoming dividend of US$0.80 per share at 1.0% yield

Stryker Corporation (NYSE:SYK) executed a binding offer to acquire Serf from SAS Menix.

Stryker Corporation, Annual General Meeting, May 09, 2024

Stryker Corporation Announces Dr. Srikant Datar Will Retire from Board of Directors

Stryker Corporation Declares Quarterly Dividend, Payable on January 31, 2024

Stryker Corporation Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$1.82 (vs US$2.16 in 3Q 2022)

Stryker to Showcase Q Guidance System with Spine Guidance Software

Stryker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Upcoming dividend of US$0.75 per share at 1.0% yield

Stryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions

Stryker Corporation Releases Its Next-Generation of Advanced Surgical Cameras

Stryker’S Pangea Systems Receive Food & Drug Administration Clearance

Key Executive recently sold US$1.4m worth of stock

Stryker Corporation Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$1.94 (vs US$1.73 in 2Q 2022)

Stryker Corporation to Report Q2, 2023 Results on Aug 03, 2023

Upcoming dividend of US$0.75 per share at 1.0% yield

Independent Director recently sold US$139k worth of stock

Surgeons Successfully Complete First Surgical Cases Using Stryker’s Q Guidance System with Cranial Guidance Software

Independent Director recently sold US$286k worth of stock

Stryker Corporation Declares Quarter Dividend, Payable on July 31, 2023

First quarter 2023 earnings released: EPS: US$1.56 (vs US$0.85 in 1Q 2022)

Upcoming dividend of US$0.75 per share at 1.1% yield

Stryker’s Q Guidance System for Cranial Applications Receives FDA Clearance

Stryker Declares Quarterly Dividend, Payable on April 28, 2023

VP & CFO recently sold US$6.8m worth of stock

Full year 2022 earnings released: EPS: US$6.24 (vs US$5.29 in FY 2021)

Stryker Corporation Provides Earnings Guidance for the Year 2023

Stryker Corporation to Report Q4, 2022 Results on Jan 31, 2023

Upcoming dividend of US$0.75 per share

Stryker Launches Citrefix™ Suture Anchor System

Stryker Corporation Declares Quarterly Dividend, Payable January 31, 2023

Independent Director recently sold US$64k worth of stock

Stryker Opens the OR of the Future for Customers to Experience Tomorrow's OR

Insider recently sold US$75k worth of stock

Now 20% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$2.16 (vs US$1.16 in 3Q 2021)

Stryker Corporation Provides Earnings Guidance for the Year 2022